Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.30% | 118.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.78% | 81.16% | |||
| Operating Income | -33.78% | -73.85% | |||
| Income Before Tax | -13.98% | -53.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.98% | -53.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.98% | -53.70% | |||
| EBIT | -33.78% | -73.85% | |||
| EBITDA | -33.47% | -- | |||
| EPS Basic | 84.92% | 96.44% | |||
| Normalized Basic EPS | 83.84% | 96.44% | |||
| EPS Diluted | 84.92% | 96.44% | |||
| Normalized Diluted EPS | 83.84% | 96.44% | |||
| Average Basic Shares Outstanding | 655.83% | 4,212.46% | |||
| Average Diluted Shares Outstanding | 655.83% | 4,212.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||